An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
DiaMedica Therapeutics to Participate at Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
DiaMedica Therapeutics (NASDAQ: DMAC) will participate in three investor conferences from September 13 to September 23, 2021. The H.C. Wainwright 23rd Annual Global Investment Conference will take place from September 13-15, featuring one-on-one meetings and an on-demand presentation starting at 7:00 am ET. The Lake Street Capital Best Ideas Growth Conference is scheduled for September 14-15, followed by the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit from September 20-23, both including one-on-one meetings. For more details, visit their website.
Positive
None.
Negative
None.
MINNEAPOLIS--(BUSINESS WIRE)--
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the company will participate in three upcoming investor conferences. Details of the company’s participation are as follows:
Conference: H.C. Wainwright 23rd Annual Global Investment Conference Dates: September 13th – 15th, 2021
Format: One-on-one meetings, on-demand corporate presentation beginning September 13th at 7:00am ET
Conference: Lake Street Capital Best Ideas Growth (BIG5) Conference Dates: September 14th – 15th, 2021
Format: One-on-one meetings
Conference: Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit
Dates: September 20th – 23rd, 2021
Format: One-on-one meetings
For more information or to schedule a one-on-one meeting with management, please contact your conference representative.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics is a clinical stage biopharmaceutical company committed to improving the lives of people suffering serious diseases. Our lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic stroke (AIS) and chronic kidney disease (CKD). Based on promising early clinical results, we are advancing DM199 in our REMEDY Phase 2/3 trial in the treatment of AIS and completing enrollment in our REDUX Phase 2 trial for the treatment of certain rare and significant unmet causes of CKD. For more information visit our website at www.diamedica.com.
For Investor Inquiries:
Tim McCarthy Managing Director, LifeSci Advisors, LLC tim@lifesciadvisors.com
Source: DiaMedica Therapeutics Inc.
FAQ
What investor conferences will DiaMedica Therapeutics participate in September 2021?
DiaMedica Therapeutics will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, Lake Street Capital Best Ideas Growth Conference, and Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit in September 2021.
What are the dates for the H.C. Wainwright Conference?
The H.C. Wainwright 23rd Annual Global Investment Conference will be held from September 13 to September 15, 2021.
What is the format of the conferences DiaMedica will attend?
The format for the conferences will include one-on-one meetings and an on-demand corporate presentation for the H.C. Wainwright Conference.
What is the stock symbol for DiaMedica Therapeutics?
The stock symbol for DiaMedica Therapeutics is DMAC.
What is the significance of DM199 for DiaMedica Therapeutics?
DM199 is DiaMedica's lead candidate aimed at treating acute ischemic stroke and chronic kidney disease, being advanced in pivotal clinical trials due to early promising results.
